Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict lung decline in rare disease

NCT ID NCT04844359

Knowledge-focused Sponsor: National Jewish Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking for markers in the blood that can predict whether a person's chronic hypersensitivity pneumonitis will get worse over time. Researchers will follow about 137 patients at 7 U.S. centers for 24 months, tracking lung function, symptoms, and CT scans. The goal is to develop a tool that helps doctors personalize care, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test that helps doctors predict which patients with chronic hypersensitivity pneumonitis will get worse, allowing for earlier and more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. It is relatively small (137 people) and only looks for patterns in the blood. The findings may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

137 people

The number who actually took part.

Started

Jan 2021

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of men and women aged 18 to 85 years old with a diagnosis of chronic hypersensitivity pneumonitis.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of chronic hypersensitivity pneumonitis * Age 18 through 85 years. * Diagnosis of chronic hypersensitivity pneumonitis by HRCT * Able to understand and sign a written informed consent form. * Able to understand the importance of adherence to the study protocol and willing to follow all study requirements Exclusion Criteria: * Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study * Known explanation for the interstitial lung disease * Clinical diagnosis of any connective tissue disease * Listed or expected to receive a lung transplant within 4 months from enrollment * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypersensitivity pneumonitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypersensitivity pneumonitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypersensitivity pneumonitis

Contacts and locations

Locations

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • National Jewish Health

    Denver, Colorado, 80206, United States

  • University of Arizona

    Tucson, Arizona, 85719, United States

  • University of California Davis

    Sacramento, California, 95817, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Texas Southwestern

    Dallas, Texas, 75390, United States

  • University of Utah

    Salt Lake City, Utah, 84108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.